Prof Ranga Krishnan MB ChB
Dean of Rush Medical College and senior vice president of Rush University Medical Center. From 2009 to 2015, he was Dean at Duke-NUS Graduate Medical School Singapore. Before, he was Professor and the Chairman of the Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina for eleven years, until June 2009. Has received numerous awards from various international scientific bodies. He has over 400 peer reviewed publications and numerous books and book chapters. Dr. Krishnan serves or has served on many editorial boards of scientific journals and on multiple research review panels for the National Institutes of Health.
Dr. Ravi Anand, M.D.
Chief Medical Officer, Newron Pharmaceuticals. For over 20 years, Dr. Anand has worked in international drug development and registration departments of major pharmaceutical companies, including F. Hoffmann-La Roche (Switzerland), Sandoz/Novartis (United States) and Organon (Netherlands). Overall, he has been responsible for the conduct of clinical trials in over 30 countries. He has been involved in over 30 investigational new drug applications, and over 7 international new drug applications. He has published extensively, including over 50 papers and 200 abstracts, posters and presentations.
Dr. Atul Pande, M.D.
President of Verity BioConsulting, Inc. He is also a non-executive member of the board of directors of Autifony Therapeutics Ltd,UK. Previously he was Senior Vice President and Senior Advisor, Pharmaceutical R&D at GlaxoSmithKline Corporation. For more than two decades he has been active in the development of many important CNS drugs while holding various senior roles in Pfizer R&D, Parke-Davis/Warner-Lambert, and Lilly Research Laboratories. Dr.Pande is a psychiatrist and Fellow of several scientific societies. He has published over 50 peer-reviewed scientific papers and over 100 abstracts, book chapters, and book reviews.